Siltuximab interferes with IL-6-mediated B lymphocyte and plasma cell growth, vascular endothelial growth factor (VEGF) secretion, and autoimmunity (Fajgenbaum and Kurzrock 2016). Here, VEGFA is linked to Autoimmunity.